If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNuformix Regulatory News (NFX)

Share Price Information for Nuformix (NFX)

Share Price is delayed by 15 minutes
Get Live Data
0.175    -0.005 (-2.78%)
Bid:
0.17
Ask:
0.18
Spread: 0.01 (5.882%)
Market Cap: £4.57m
NFX Live PriceLast checked at - London Stock Exchange

Intraday Nuformix Share Chart

Director/PDMR Shareholding

31 Jan 2022 14:09

RNS Number : 1883A
Nuformix PLC
31 January 2022
Β 

Β 

31 January 2022

Nuformix plc

Β 

("Nuformix" or the "the Company")

Β Β 

Director/PDMR Shareholding

Β 

Nuformix plcΒ (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that it has granted a total of 3,000,000 warrants each to Dr Alastair Riddell, Dr Julian Gilbert and Maddy Kennedy with an exercise price of 1.45p per share.

Β 

- Ends -

Β 

Β Enquiries:

Nuformix plc

via Walbrook

DrΒ Alastair Riddell, Executive Chairman

Β 

Allenby Capital Limited

Β 

+44 (0) 20 3328 5656

Nick AthanasΒ /Β George PayneΒ (Corporate Finance)

Stefano AquilinoΒ /Β Matt ButlinΒ (Sales and Corporate Broking)

Β 

Walbrook PR

Β 

nuformix@walbrookpr.comΒ orΒ +44 (0)20 7933 8780

Anna DunphyΒ /Β Phillip Marriage

Tel: +44 (0)7876 741 001 / +44 (0)7867 984 082

Β 

Β 

Β 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

Β 

Β 

1

Β 

Details of the person discharging managerial responsibilities / person closely associated

Β 

a)

Β 

Name

Β 

Dr Alastair Riddell

2

Β 

Reason for the notification

Β 

a)

Β 

Position/status

Β 

PDMR - Executive Chairman

b)

Β 

Initial notification /Amendment

Β 

Initial notification

3

Β 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Β 

a)

Β 

Name

Β 

Nuformix plc

b)

Β 

LEI

Β 

2138003XG3H3I2J3BJ24

4

Β 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Β 

a)

Β 

Description of the financial instrument, type of instrument

Β 

Identification code

Β 

Warrants to acquire ordinary shares at a price of 1.45p per share.

Β 

Β 

GB00BYW79Y38

b)

Β 

Nature of the transaction

Β 

Granting of warrants

c)

Β 

Price(s) and volume(s)

Β 

Β 

Β 

Price(s)

Β 

Volume(s)

0

Β 

3,000,000

Β 

d)

Β 

Aggregated information

Single Transaction

Β 

e)

Β 

Date of the transaction

Β 

31 January 2022

f)

Β 

Place of the transaction

Β 

Off-market transaction

Β 

1

Β 

Details of the person discharging managerial responsibilities / person closely associated

Β 

a)

Β 

Name

Β 

Dr Julian Gilbert

2

Β 

Reason for the notification

Β 

a)

Β 

Position/status

Β 

PDMR - Non-executive Director

b)

Β 

Initial notification /Amendment

Β 

Initial notification

3

Β 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Β 

a)

Β 

Name

Β 

Nuformix plc

b)

Β 

LEI

Β 

2138003XG3H3I2J3BJ24

4

Β 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Β 

a)

Β 

Description of the financial instrument, type of instrument

Β 

Identification code

Β 

Warrants to acquire ordinary shares at a price of 1.45p per share.

Β 

Β 

GB00BYW79Y38

b)

Β 

Nature of the transaction

Β 

Issue of warrants

c)

Β 

Price(s) and volume(s)

Β 

Β 

Β 

Price(s)

Β 

Volume(s)

0

Β 

3,000,000

Β 

d)

Β 

Aggregated information

Single Transaction

Β 

e)

Β 

Date of the transaction

Β 

31 January 2022

f)

Β 

Place of the transaction

Β 

Off-market transaction

Β 

1

Β 

Details of the person discharging managerial responsibilities / person closely associated

Β 

a)

Β 

Name

Β 

Maddy Kennedy

2

Β 

Reason for the notification

Β 

a)

Β 

Position/status

Β 

PDMR - Non-executive Director

b)

Β 

Initial notification /Amendment

Β 

Initial notification

3

Β 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Β 

a)

Β 

Name

Β 

Nuformix plc

b)

Β 

LEI

Β 

2138003XG3H3I2J3BJ24

4

Β 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Β 

a)

Β 

Description of the financial instrument, type of instrument

Β 

Identification code

Β 

Warrants to acquire ordinary shares at a price of 1.45p per share.

Β 

Β 

GB00BYW79Y38

b)

Β 

Nature of the transaction

Β 

Issue of Warrants

c)

Β 

Price(s) and volume(s)

Β 

Β 

Β 

Price(s)

Β 

Volume(s)

0

Β 

3,000,000

Β 

d)

Β 

Aggregated information

Single Transaction

Β 

e)

Β 

Date of the transaction

Β 

31 January 2022

f)

Β 

Place of the transaction

Β 

Off-market transaction

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
DSHWPUMUGUPPGCG
Date   Source Headline
22nd May 20237:00 amRNSUnaudited Interim Report
18th May 20237:00 amRNSNXP002 Inflammation and Duration of Action Update
26th Apr 202310:55 amRNSHolding(s) in Company
17th Apr 20237:00 amRNSSubscription to raise £70,000 & issue of Warrants
27th Mar 20237:00 amRNSNXP002 Update
13th Mar 20237:00 amRNSChange of Accounting Reference Date
15th Feb 20237:00 amRNSNXP002 Update
3rd Jan 20231:37 pmRNSHolding(s) in Company
20th Dec 20221:02 pmEQSNuformix hoping to 'initiate discussions with major pharma' in 2023
20th Dec 20227:00 amRNSNXP004 Update
13th Dec 20227:00 amRNSHalf-year Report
5th Dec 20227:00 amRNSResignation of Auditor
16th Nov 20228:50 amRNSHolding(s) in Company
4th Nov 20227:00 amRNSInvestor Webinar
23rd Sep 20227:00 amRNSNXP002 Update
23rd Sep 20227:00 amRNSNXP002 Update
25th Aug 20222:39 pmRNSResult of AGM
19th Aug 20228:57 amRNSHolding(s) in Company
10th Aug 20227:00 amRNSNXP002 Completion of Tolerability Studies
1st Aug 202212:13 pmRNSPosting of Annual Report and Notice of AGM
28th Jul 20227:01 amRNSBoard Changes
28th Jul 20227:00 amRNSAnnual Results for the year ended 31 March 2022
5th Jul 20227:00 amRNSNXP002 data to be presented at 2022 ERS Congress
29th Jun 20227:00 amRNSNXP004 Update
27th Jun 20227:00 amRNSNXP002 Update
20th Jun 20227:00 amRNSHolding(s) in Company
31st May 20227:00 amRNSDirectorate Change
30th May 20227:00 amRNSCorporate Update
12th Apr 20227:00 amRNSSecond tranche of Lanstead subscription shares
11th Apr 20223:54 pmRNSHolding(s) in Company
8th Apr 202211:21 amRNSHolding(s) in Company
7th Apr 20223:44 pmRNSHolding(s) in Company
5th Apr 20226:07 pmRNSHolding(s) in Company
28th Mar 20227:00 amRNSNXP004 Patent
2nd Mar 20227:00 amRNSAppointment of Dr Dan Gooding as Consultant
1st Mar 20227:00 amRNSChange of Auditor
14th Feb 20224:37 pmRNSHolding(s) in Company
8th Feb 20227:00 amRNSOxilio NXP-001 formulation development contract
1st Feb 20227:00 amRNSAdviser Appointments
31st Jan 20222:09 pmRNSDirector/PDMR Shareholding
31st Jan 202211:05 amRNSResult of General Meeting
17th Jan 20229:56 amRNSPosting of Circular and Notice of General Meeting
10th Jan 20224:23 pmRNSDirector/PDMR Shareholding
21st Dec 20217:00 amRNSHolding(s) in Company
14th Dec 20212:05 pmRNSSecond Price Monitoring Extn
14th Dec 20212:00 pmRNSPrice Monitoring Extension
14th Dec 20217:01 amRNSSubscription to raise £1.65 million
14th Dec 20217:00 amRNSHalf year Report
25th Nov 20217:00 amRNSPositive pre-clinical data on NXP002
17th Nov 20219:34 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.